UP!

ALR $50.99   View long term graphs

Alere Inc.
Type
Public
Traded as NYSE: ALR
Industry health care diagnostics
Founded 1991
Headquarters Waltham, Massachusetts, United States
Area served
Worldwide
Revenue $2.39 billion (As of 2017)
Website www.alere.com

Alere Inc. is a global manufacturer of rapid point-of-care diagnostic tests. The company was founded in 2001 and is headquartered in Waltham, Massachusetts. As of January 2017, the company has a market capitalization of $3.47 billion with an enterprise value of $5.9 billion. The company was formerly known as Inverness Medical Innovations, Inc. and changed its name to Alere Inc. in 2010.

The company was founded in 1991 by Ron Zwanziger under the Name SelfCare, which went public in 1996. The company changed its name from SelfCare to Inverness Medical Technology (IMT) in 2000. One year later, it sold its diabetes business to Johnson & Johnson, and split off a new company called Inverness Medical Innovations. That company subsequently expanded its business by acquiring many companies, including Unipath, Clondiag, Ionian Technologies, TwistDx, Wampole Laboratories, Ostex International, Binax, Biosite, HemoSense, Cholestech, Redwood Toxicology, Concateno, BBI Holdings, eScreen, Standard Diagnostics, and hhh Axis-Shield.

In 2007, Alere entered into a joint venture, named Swiss Precision Diagnostics, with Procter & Gamble for the sales and marketing of its consumer diagnostics products.

In 2009, Alere won two awards in the 16th Annual National Health Information program, which recognizes the U.S.’s best consumer health information programs and materials.

In 2010, the company changed its name to Alere and began trading under the ticker ALR in NYSE.

In 2013, the company completed the acquisition of Epocal, Inc.

In July 2014 Ron Zwanziger resigned as CEO and COO Namal Nawana took over as interim CEO.

In September 2014, Zwanziger offered to take the company private for $3.82 billion.

In October 2014, the Board of Directors voted and instated Namal Nawana as the permanent CEO of Alere, Inc.

In early 2015, Alere divested its Alere Health management activities to Optum.

In February 2016, Abbott Laboratories announced it would acquire Alere Inc for $5.8 billion. However, in April, Abbott requested of Alere that this deal be terminated, a proposal rejected by Alere's board of directors.

In October 3, 2017, Abbott Laboratories closed the Alere acquisition making the surviving entity the market leader player in the $7 billion point-of-care diagnostic space within the broader $50 billion in-vitro diagnostics market with this takeover. With the acquisition of Alere,the company also obtain the subsidiary Arriva Medical, which is the largest mail-order diabetic supplier.

Alere operates three business units focused on cardiometabolic, infectious disease, and toxicology testing. The company pioneers in manufacturing rapid point-of-care diagnostic tests and provides products to healthcare professionals and patients worldwide.

In 2004, the company launched the world's first digital pregnancy test under Clearblue® Digital Pregnancy Test.

In 2010, Alere launched the Alere CD4 analyser, the world’s first to provide absolute CD4 results at the Point of Care, making the management of HIV patients easier and more effective.

October 2012, the company received a warning from the Food and Drug Administration (FDA) for its inadequate response to FDA’s earlier observations on its manufacturing process of the Triage products.

In 2014 Alere received clearance from US FDA for the Alere i Influenza A&B, a rapid molecular point-of-care test to detect and differentiate Influenza A&B virus in less than 15 minutes. In Jan 2015, Alere received US CLIA waiver for the Alere i Influenza test. In April 2015, Alere received FDA clearance for its second test on the Alere i platform, the Alere i Strep A test for Group A Streptococcus, which provides results in 8 minutes or less.

In March 2015 Alere received IVD CE mark for Alere q HIV analyser, a fully automated nucleic acid testing platform which brings the power of molecular testing to bench tops in any healthcare setting.

In August 2016 Alere received FDA Clearance for Alere i RSV Rapid Molecular Test which detects RSV infections in 13 minutes or less.

In 2016 the U.S. Justice Department launched an investigation into Alere's role in potential Medicaid and Medicare fraud.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2017 2018-02-12 Future report Set alerts
Q3 2017 2017-11-02 Future report Set alerts
Q2 2017 2017-08-03 0.12 -1.13
Q1 2017 2017-06-14 0.43 -0.80
Q4 2016 2017-05-22 0.64 -1.37
Q3 2016 2016-11-04 0.46 0.12
Q1 2016 2016-09-06 0.51 -0.13
Q2 2016 2016-09-06 0.42 -0.44
Q4 2015 2016-08-08 0.60 -0.31
Q3 2015 2015-11-04 0.54 -0.08

Ratings

2016-07-12 Reiterated Rating Jefferies Group Hold
2016-07-12 Reiterated Rating Leerink Swann Buy
2016-04-30 Reiterated Rating Canaccord Genuity Hold
2016-04-29 Upgrade Craig Hallum Hold to Buy
2016-04-28 Upgrade Leerink Swann Market Perform to Outperform $56.00
2016-04-27 Upgrade Leerink Partner Market Perform to Outperform
2016-04-27 Upgrade Leerink Swann Market Perform to Outperform
2016-04-21 Reiterated Rating Jefferies Group Hold
2016-04-21 Reiterated Rating Canaccord Genuity Hold $46.00
2016-03-16 Reiterated Rating Canaccord Genuity Hold $56.00
2016-03-15 Downgrade BTIG Research Buy to Neutral
2016-02-29 Reiterated Rating Canaccord Genuity Hold $56.00
2016-02-02 Reiterated Rating Craig Hallum Buy to Hold $56.00
2016-02-02 Downgrade Canaccord Genuity Buy to Hold $52.00 to $56.00
2016-02-02 Downgrade Raymond James Outperform to Market Perform
2016-02-02 Downgrade Jefferies Group Buy to Hold $54.00 to $56.00
2016-02-02 Boost Price Target Leerink Swann Market Perform $50.00 to $56.00
2016-02-02 Downgrade Raymond James Financial Inc. Outperform to Market Perform
2016-02-01 Downgrade Goldman Sachs Buy to Neutral $47.00 to $56.00
2016-02-01 Reiterated Rating Canaccord Genuity Buy to Hold $52.00 to $56.00
2016-02-01 Downgrade Goldman Sachs Group Inc. Buy to Neutral $47.00 to $56.00
2016-01-11 Reiterated Rating BTIG Research Buy $60.00
2016-01-04 Reiterated Rating BTIG Research Buy
2015-12-29 Reiterated Rating BTIG Research Buy $60.00
2015-12-22 Lower Price Target Goldman Sachs Buy $53.00 to $50.00
2015-11-08 Reiterated Rating BTIG Research Buy $65.00
2015-11-05 Lower Price Target Canaccord Genuity Buy $60.00 to $52.00
2015-11-05 Lower Price Target Leerink Swann $50.00
2015-11-05 Lower Price Target Wedbush Neutral $43.00 to $39.00
2015-11-02 Boost Price Target Wedbush $38.00 to $41.00
2015-11-02 Boost Price Target Raymond James Strong-Buy $46.00 to $50.00
2015-11-02 Boost Price Target Leerink Swann Market Perform $42.00 to $44.00
2015-11-02 Reiterated Rating Canaccord Genuity Buy $60.00 to $52.00
2015-10-23 Reiterated Rating BTIG Research Buy $65.00
2015-08-12 Reiterated Rating BTIG Research Buy $65.00
2015-08-05 Reiterated Rating Leerink Swann Hold $50.00 to $55.00
2015-08-04 Reiterated Rating Canaccord Genuity Buy $60.00
2015-08-04 Reiterated Rating BTIG Research Buy $65.00
2015-07-23 Reiterated Rating BTIG Research Buy $65.00
2015-07-16 Initiated Coverage Canaccord Genuity Buy $60.00
2015-07-16 Reiterated Rating BTIG Research Buy $65.00
2015-06-23 Upgrade Goldman Sachs Neutral to Buy $50.00 to $60.00
2015-06-23 Boost Price Target Raymond James Strong-Buy $57.00 to $60.00
2015-05-26 Initiated Coverage Canaccord Genuity Buy $56.00 to $60.00
2015-05-09 Reiterated Rating Goldman Sachs Neutral $47.00 to $50.00
2015-05-06 Reiterated Rating BTIG Research Buy $65.00
2015-05-06 Reiterated Rating Canaccord Genuity Buy $56.00
2015-05-06 Boost Price Target Jefferies Group Buy $55.00 to $56.00
2015-04-07 Boost Price Target Canaccord Genuity Buy $50.00 to $56.00
2015-04-02 Set Price Target Canaccord Genuity Buy $50.00 to $56.00
2015-03-26 Upgrade Goldman Sachs Sell to Neutral $42.00 to $47.00
2015-03-23 Set Price Target BTIG Research Buy $55.00
2015-03-20 Boost Price Target Jefferies Group Buy $50.00 to $55.00
2015-03-13 Boost Price Target Leerink Swann Market Perform $44.00 to $50.00
2015-03-11 Reiterated Rating Canaccord Genuity Buy $50.00
2015-03-09 Reiterated Rating BTIG Research Buy $55.00
2015-02-12 Downgrade Citigroup Inc. Market Weight
2015-02-12 Reiterated Rating Canaccord Genuity Buy $46.00 to $50.00
2015-02-11 Reiterated Rating Jefferies Group Buy $48.00 to $50.00
2015-02-11 Set Price Target Wedbush Neutral $38.00 to $41.00
2015-02-09 Set Price Target BTIG Research Buy $52.00
2015-02-04 Boost Price Target Canaccord Genuity Buy $46.00 to $50.00
2014-10-29 Upgrade Craig Hallum Hold to Buy
2014-10-03 Initiated Coverage ING Group Buy $48.00
2014-10-02 Initiated Coverage BTIG Research Buy
2014-09-16 Boost Price Target Leerink Swann $38.00 to $45.00
2014-09-16 Boost Price Target Canaccord Genuity Buy $45.00 to $46.00
2014-09-03 Downgrade Goldman Sachs Neutral to Sell
2014-08-05 Lower Price Target Jefferies Group Buy $45.00 to $40.00
2014-08-05 Lower Price Target Leerink Swann Market Perform $40.00 to $38.00
2014-08-05 Lower Price Target Canaccord Genuity $50.00 to $45.00
2014-07-10 Boost Price Target Canaccord Genuity Buy $45.00 to $50.00
2014-05-01 Upgrade Craig Hallum Sell to Hold
2014-04-30 Reiterated Rating Leerink Swann Market Perform $38.00 to $36.00
2014-03-24 Boost Price Target Leerink Swann $36.00 to $38.00
2014-01-10 Boost Price Target Wunderlich Buy $40.00 to $45.00
2013-12-18 Initiated Coverage JMP Securities Mkt Perform to Outperform $45.00
2013-11-25 Boost Price Target Jefferies Group $50.00
2013-05-10 Reiterated Mizuho Neutral $20 to $25
2013-02-19 Reiterated Mizuho Neutral $18 to $20
2012-08-09 Reiterated Mizuho Neutral $27 to $18
2012-05-24 Downgrade Capstone Investments Buy to Hold $32 to $32
2012-02-09 Reiterated RBC Capital Mkts Sector Perform $22 to $25
2011-07-29 Downgrade Wedbush Outperform to Neutral $41 to $31
2011-07-27 Downgrade JMP Securities Mkt Outperform to Mkt Perform
2011-02-18 Reiterated Wedbush Outperform $37 to $44
2011-01-04 Initiated Wunderlich Buy $49
2010-12-13 Reiterated JMP Securities Mkt Outperform $34 to $42
2010-11-16 Initiated Canaccord Genuity Buy $40
2010-11-02 Reiterated JMP Securities Mkt Outperform $37 to $34
2010-07-29 Reiterated Wedbush Outperform $38 to $36
2016-07-12 Reiterated Rating Jefferies Group Hold
2016-07-12 Reiterated Rating Leerink Swann Buy
2016-04-30 Reiterated Rating Canaccord Genuity Hold
2016-04-29 Upgrade Craig Hallum Hold to Buy
2016-04-28 Upgrade Leerink Swann Market Perform to Outperform $56.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
ZWANZIGER RON Chairman, CEO & President 2.17%  (1806696) ALR /

Comments